KLK11抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P08467(KLK11 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08467(KLK11 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The KLK11 antibody is designed to target kallikrein-related peptidase 11 (KLK11), a serine protease encoded by the *KLK11* gene. This enzyme belongs to the human tissue kallikrein family, which comprises 15 members (KLK1-KLK15) involved in diverse physiological processes, including tissue remodeling, hormone processing, and inflammation. KLK11 is expressed in various tissues, such as the prostate, breast, and central nervous system, and is detectable in biological fluids like serum, urine, and seminal plasma. Its enzymatic activity is linked to the cleavage of extracellular matrix proteins and peptide hormones, suggesting roles in cancer progression, neurodegeneration, and reproductive functions.

Elevated KLK11 levels have been associated with prostate, ovarian, and lung cancers, positioning it as a potential diagnostic or prognostic biomarker. Antibodies against KLK11 are primarily used in research and diagnostics to quantify protein expression via techniques like ELISA, immunohistochemistry, or Western blotting. Some therapeutic applications are under exploration, such as blocking KLK11’s proteolytic activity in cancer or leveraging antibody-drug conjugates for targeted therapy. However, clinical utility remains investigational, with ongoing studies focused on validating its specificity, biological relevance, and therapeutic potential.